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1. Introduction 
Cancer is a leading cause of death world wide and mortality due to this group of diseases has 
doubled in the last 20 years. With an estimated 3 million cases, skin cancer is currently the 
third most common human malignancy and global incidence is rising at an alarming rate due 
to environmental changes. Within that category, melanomas represent the least common, but 
most dangerous form accounting for the majority of skin cancer-related deaths.  
In general terms, cancer evolves as the consequence of a multi-factorial process that involves 
the loss of a cell’s ability to respond in an appropriate fashion to cues provided by the 
microenvironment. The development of such aberrant, autonomous behavior is caused by 
both genetic mutations and epigenetic mechanisms. Particularly relevant in the context of 
melanoma are the Ras/Raf/MEK/Erk, PI3K/PTEN and NF-kB signaling pathways. The 
Wnt/┚-catenin patway is also implicated, but it´s role still remains unclear. Depending on 
whether changes result in a “gain of function” or a “loss of function”, the molecules 
involved are classified as either oncogenes or tumor suppressors, examples important in 
melanomas being NRas and B-Raf or PTEN, respectively. More recently, a new group of 
molecular participants has begun to emerge, which, depending on the cellular context, 
display the ability to either block tumor development or favor progression. Very little is still 
known about the underlying mechanisms that might explain such “ambiguous” behavior.  
In this respect, work from our laboratory has focused on the study of a scaffolding protein 
called caveolin-1. This protein is implicated in a large number of cellular processes, including 
caveolae formation and vesicular transport, cholesterol transport and the regulation of signal 
transduction. With respect to tumor development, initial reports implicated caveolin-1 as a 
tumor suppressor. For instance, caveolin-1 expression is reduced in several human tumors 
including lung, mammary, colon, ovarian carcinoma and sarcomas, as wells as osteosarcomas 
and re-expression of the protein can reverse characteristics associated with the transformed 
phenotype. However, evidence to the contrary is also available showing that caveolin-1 
promotes more aggressive traits in tumor cells, such as metastasis and multidrug resistance. 
Importantly, in human melanoma patients high levels of caveolin-1 are detected in exosomes 
found in the plasma and some data available associate caveolin-1 expression with increased 
metastatic potential in different human melanoma cell lines.  
In this chapter, we summarize data available in the literature highlighting the ambiguity of 
caveolin-1 function in cancer development. Mechanisms that might explain one or the other 
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type of behavior, as well as the possible relevance of caveolin-1 in the development of 
melanomas will be discussed. Finally, the potential of this understanding for developing 
therapies will be mentioned. 
2. Cancer 
Cancer is a leading cause of death worldwide that evolves as the consequence of genetic and 
epigenetic changes (Ponder 2001). This multifactorial process results in the loss of 
appropriate communication between cells and their microenviroment. During this 
transition, aberrant cells acquire specific molecular traits, including unlimited replicative 
potential, resistance to apoptosis, independence of growth factors and insensitivity to 
growth-inhibitory signals. Insipient tumors require then the formation de novo of blood 
vessels (angiogenesis) to grow beyond an initially limited size. Ultimately, tumor cells 
develop the ability to disseminate to distant sites and form new tumors (metastasis), which 
frequently are the cause of patient death. All these processes are thought to reflect the 
consequence of an inbalance in the activity of genes referred to as oncogenes and tumor 
suppressors, whereby mutations in both types of genes (genetic regulation), in addition to 
changes in the levels of expression (epigenetic regulation), contribute to such abnormal 
development (Weinberg 1989; Hanahan and Weinberg 2000; Hanahan and Weinberg 2011). 
Skin cancer is a common disease and the high incidence has generated global concern. 
Although many of these cancers are not aggressive, some, like melanoma, are extremely 
lethal. As indicated, aberrant cellular signaling underlies the development of essentially all 
tumors. Not surprisingly, therefore, in the transition from melanocytes to melanomas, many 
signaling pathways become constitutively activated, as will be discussed later and promote 
the acquisition of molecular traits associated with melanoma development. (Figure 1). 
Malignant melanomas are a serious public health problem in many countries; however, data 
from less developed countries is often either not available or not reliable. The data available 
in developed countries reveals that mortality associated with melanomas has increased 
gradually in the past 40 years. Perhaps more problematic in this context is the fact that the 
incidence rate is increasing faster in younger people, an aspect which tends to amplify the 
impact of this deadly cancer. Malignant melanoma is known to initially develop in 
melanocytes located at the interphase between epidermis and dermis. These peripherally 
located, proliferative cells suffer damage upon excessive UV exposure that can translate 
ultimately into cell transformation and invasion of deeper structures of the skin. While still 
at an early stage of development, equivalent to less than 4 mm of vertical penetration and 
the absence of distant spread, surgical resection represents an appropriate treatment for 
melanomas. However, in more advanced cases, the success of surgical and therapeutical 
procedures is severely limited by tumor recurrence, metastasis and relatively rapid patient 
death. Hence, in order to develop more effective treatments, it is important to understand 
better the mechanisms leading to melanocyte damage and, particularly, to identify those 
responsible for the alterations in signaling that initiate and propagate the transformation 
process. In recent years, a large body of evidence has accumulated identifying sun exposure 
as a mayor risk factor in developing this disease. However, simply eliminating this risk by 
protective measures is not an option, since sun exposure is necessary for a number of 
reasons, including being required for vitamin D synthesis. Hence, it is important to define 
when precisely sun exposure becomes deleterious, in order to identify groups of the 
population at risk and thereby improve early diagnosis and treatment.  
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Fig. 1. Atypical characteristics acquired by melanocytes in the transition to malignant 
melanomas  
Melanocytes are intimately associated with keratinocytes in the intermediate cell layer 
between dermis and epidermis. The acquisition of atypical features, such as uncontrolled 
proliferation, angiogenesis, anchorage-independent growth and insensitivity to death-
inducing signals are depicted. Additionally, the cells eventually begin to migrate, become 
invasive and metastatic. These cells invade both the dermis and epidermis layers, thereby 
increasing the size of the primary tumor before disseminating via the blood stream to other 
tissues. 
3. Melanoma incidence 
The International Agency for Research on cancer publishes a document entitled “Cancer 
Incidence in Five Continents”, which permits comparisons between countries. In general 
terms, countries with white/Kaukasian-populations have the highest incidence rates (above 
2/100.000) in the world, while asians, africans and indigenous americans are much less at 
risk (1-0.1/100.000). The highest registered incidence for melanomas in the world is found in 
Australia, whereby a latitude gradient exists, such that rates are highest in the northern part 
of the country (over 50/100.000 in men, and 40/100.000 for women). Also in New Zealand 
the incidence of 30/100.000 is well above the global average and higher to the north. Given 
that in both these countries the predominantly white population is homogeneously 
distributed, differences is incidence rates can be largely explained by the latitude gradient in 
sun exposure. Amongst european countries, Scandinavia and Switzerland have the highest 
incidence rates, being in the latter case 16/100.000 for men and 19/100.000 for women. For 
Scandinavian countries, there is no straightforward explanation, although the population is 
extremely fair, because sun exposure is low. In Switzerland, ozone depletion may be a 
relevant factor. Interestingly, Italy also has latitude a gradient which is inverted compared 
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to the one in Australia, such that for residents of northern regions (less sun exposure) 
incidence rates are higher than in southern regions with increased exposure. The question 
arising here is whether a “skin gradient” exists within the Italian population. Also in the 
USA incidence rates are quite high, but only in non-hispanic, white populations (19/100.000 
men, 16/100.000 women). Relevant factors are again the ethnic background and sun 
exposure. However, no latitude gradient has been described in the USA. For the rest of the 
world, the incidence appears low. However, data is frequently either not available or not 
reliable, in the latter case mainly due to confusion with non-melanoma skin cancer. 
A this point, we wish to dwell briefly on the problem of malignant melanoma in Chile. This 
narrow and extremely long country (approx. 200 by 5000 km) extends from 18°S to 55°S and 
covers, therefore, geographical zones particularly in the center and to the north with intense 
sun exposure. Moreover, UV irradiation has also increased dramatically in the southern-
most region (ie: XII region) close to the Antarctic, due to ozone depletion that has become 
evident since the 1970s. Consistent with this development, epidemiological data 
accumulated over the last 30-40 years indicate a notable increment in the incidence of 
melanomas also in these areas. The genetic background of the population is fairly 
homogeneous, being predominantly a mixture between the indigenous population of asian 
origin and europeans, whereby interracial mixing has occurred over the last 500 years. The 
population is homogeneously distributed, such that this factor does not contribute to the 
latitude gradient. In any case, available epidemiological studies do not segregate data 
according to ethnic background. 
Malignant melanoma is a relevant public health problem given the prevalence throughout 
the country and the relatively high mortality rate associated with this disease (slightly above 
1:100.000 deaths/year). Currently, melanomas are the 9th most frequent cause of cancer 
death in Chile. Unfortunately, as mentioned previously, for a large number of countries in 
the world, no useful incidence data is available due to registration problems and confusion 
with non-melanoma skin cancer. The mortality rate within the country ranges from about 
3.0/100.000 inhabitants (in the northern-most region of Chile) down to 1.2/100000 in the 
southern region (XI region). However, in the region furthest south in Chile (XII), death rates 
are again higher and reach values of approximately 2.1/100.000. For malignant melanoma, 
certain differences in body distribution  are observed for Chile in comparison to melanomas 
in Europe, North America, Australia and New Zealand. In Chile the most frequent cases are 
of the acral-lentiginous type, that are observed in non sun-exposed regions of the skin, such 
as hand palms, foot soles and under the nails. For the other countries mentioned, in most 
cases the body, face and arms are affected, suggesting sun exposure as an important causing 
factor. Treatments for malignant melanoma in Chile are similar to those employed in the 
other countries. Generally, surgical resection of large areas, with or without removal of 
sentinel lymph nodes, remains the procedure of choice.  
4. Melanoma biology  
Melanoma is a highly complex disease that involves activation of oncogenes, such as BRAF, 
NRAS, the Wnt pathway and loss or mutation of tumor suppressors, such as p53 or PTEN. 
For the subsequent discussion, we will focus in this chapter on the possible contribution of 
the Wnt/┚-catenin pathway to melanoma development. Excellent reviews concerning the 
other alterations mentioned can be found elsewhere (Straume and Akslen 1997; Larue and 
Delmas 2006; Gray-Schopfer, Wellbrock et al. 2007). 
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5. The Wnt/β-catenin pathway  
The canonical Wnt pathway is involved in the control of a large variety of processes, 
including cell proliferation, cell migration and differentiation, all key events in the initiation 
and progression of cancer. A crucial component of this pathway is ┚-catenin (Bienz and 
Clevers 2000; Polakis 2000; Widelitz 2005) (Klaus and Birchmeier 2008).  
 
 
Fig. 2. Wnt/┚-catenin pathway. 
Schematic showing some of the relevant components of the pathway and highlighting three 
key locations of ┚-catenin in the cell. On the one hand, ┚-catenin is found at the plasma 
membrane in a multiprotein complex with E-cadherin important for cell-cell interactions. 
Additionally, ┚-catenin is present in the cytosol, generally associated with another multi-
protein complex that includes adenomatous polyposis coli (APC), axin and GSK-3┚ and is 
responsible for promoting degradation via the proteasome pathway. Finally, ┚-catenin is 
also present within the nucleus, where it acts as a cofactor that promotes transcription  
by Tcf/Lef family members of a large number of genes including survivin, cox-2, cyclin D1 
and c-myc. 
In non-stimulated cells, cytoplasmic free ┚-catenin is associated within a multiprotein 
complex containing Axin/Conductin, glycogen synthase kinase 3┚ (GSK3┚/Shaggy) and the 
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tumor suppressor APC (Bienz and Clevers 2000; Polakis 2000; Henderson and Fagotto 2002; 
Nathke 2004; Heeg-Truesdell and LaBonne 2006). In this complex, Axin/Conductin acts as a 
scaffolding protein that binds APC, GSK3┚ and ┚-catenin, thereby promoting the 
phosphorylation of APC and ┚-catenin. Axin also associates with the protein kinase CK1, 
which phosphorylates ┚-catenin prior to GSK3┚ engagement and thereby promotes 
subsequent GSK3┚-dependent phosphorylation, in a process referred to as hierarchical 
phosphorylation (Heeg-Truesdell and LaBonne 2006). Subsequent phosphorylation of  
┚-catenin by GSK3┚ drives ┚-catenin ubiquitination by the SCF complex, thus promoting 
proteasome-mediated degradation of ┚-catenin (Kimelman and Xu 2006). 
Following Wnt stimulation of Frizzled receptors, Dishevelled is recruited to the receptor. 
Dishevelled binding serves to help maintain the Axin/APC/GSK3┚ protein complex in the 
vicinity of the Frizzled receptor. Additionally, this interaction favors release of ┚-catenin 
from the degradative Axin/APC/GSK3┚ protein complex, hence preventing proteasomal-
mediated degradation of ┚-catenin (Logan and Nusse 2004; Huang and He 2008). Then, ┚-
catenin translocates and accumulates in the nucleus, where it forms a protein complex with 
T-cell factor/ lymphoid enhancer factor (Tcf/Lef) transcription factors and thereby 
promotes transcription of Wnt target genes, such as cyclin D1, survivin, cox-2, c-myc (He, 
Sparks et al. 1998; Shtutman, Zhurinsky et al. 1999; Haertel-Wiesmann, Liang et al. 2000; 
Kim, Plescia et al. 2003). 
As indicated (Figure 2), another pool of ┚-catenin is present in adhesion junctions, where ┚-
catenin forms a protein complex with E-cadherin, ┙-catenin and actin. This protein complex 
has been suggested to mediate cell adhesion and confer mechanical stability to cells 
(Gottardi, Wong et al. 2001; Brembeck, Rosario et al. 2006; Jeanes, Gottardi et al. 2008; 
Schmalhofer, Brabletz et al. 2009). By sequestering ┚-catenin within the plasma membrane, 
E-cadherin reduces ┚-catenin-Tcf/Lef-dependent transcription in a manner that is 
independent of its function as a cell-cell adhesion molecule (Gottardi, Wong et al. 2001). 
Consistent with this view, loss or inactivation of E-cadherin increase responses to Wnt-
Ligands (Jeanes, Gottardi et al. 2008). Thus, E-cadherin is a negative regulator of the Wnt 
pathway and a strong inhibitor of cancer progression (Ma, Young et al. ; Berx, Nollet et al. 
1998; Gottardi, Wong et al. 2001; Hajra and Fearon 2002; Margineanu, Cotrutz et al. 2008).  
6. Alterations in the Wnt/β-catenin pathway in melanoma 
The contribution of the Wnt/┚-catenin pathway to melanoma development is highly 
controversial. Some authors suggest that Wnt/┚-catenin activation promotes melanoma 
development (Rimm, Caca et al. 1999; Larue and Delmas 2006; Larue, Luciani et al. 2009). 
This view is supported by the observation that alterations in the Wnt/┚-catenin pathway are 
detectable in 70-80% of melanomas. Specifically, mutations in ┚-catenin have been detected 
in both melanoma biopsies and melanoma cell lines (Larue and Delmas 2006).  These 
findings are reinforced by immuno-histochemical studies showing that ┚-catenin staining is 
frequently observed in primary melanomas, but is less abundant in metastatic melanomas 
(Pecina-Slaus, Zigmund et al. 2007; De Panfilis, Ferrari et al. 2009) and appears to be 
inversely correlated with the Clark stage (Pecina-Slaus, Zigmund et al. 2007). In both cases, 
┚-catenin is observed predominantly at the cell membrane and in the cytoplasm (Pecina-
Slaus, Zigmund et al. 2007; Tucci, Lucarini et al. 2007; De Panfilis, Ferrari et al. 2009). 
Furthermore, ┚-catenin has been detected in the nucleus in 30% of the melanomas analyzed 
(Rimm, Caca et al. 1999). It is important to note, that APC alterations are not frequently 
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observed in melanomas in comparison to colon cancer (Lucero, Dawson et al. ; Larue and 
Delmas 2006). However, based on such evidence it remains poorly understood how aberrant 
┚-catenin function may be related to melanoma progression. Possibly, its function in this 
sense is dependent on direct association of ┚-catenin with the promoter of Microphthalmia-
associated transcription factor (MITF), which is frequently amplified in melanoma cell lines 
(Garraway, Widlund et al. 2005) and is required for Wnt/┚-catenin to induce melanoma 
growth (Widlund, Horstmann et al. 2002). Interestingly, MITF has been proposed to 
contribute to melanoma development, by promoting expression of target genes, such as 
cdk2 that favors cell-cycle progression, anti-apoptotic bcl2, and c-met that enhances cell 
motility (Cheli, Ohanna et al. ; Levy, Khaled et al. 2006). Consistent with this view, reduction 
in MITF levels sensitizes melanoma cells to chemotherapy-induced cell death (Garraway, 
Widlund et al. 2005). 
Alternatively, other groups propose that ┚-catenin prevents melanoma progression (Lucero, 
Dawson et al. ; Kageshita, Hamby et al. 2001; Maelandsmo, Holm et al. 2003; Bachmann, 
Straume et al. 2005; Chien, Moore et al. 2009). This view is supported by clinical data 
associating more aggressive melanomas and melanoma progression with loss of ┚-catenin 
(Kageshita, Hamby et al. 2001). Consistent with this view, loss of cytoplasmic ┚-catenin 
correlates with increased thickness of lesions and reduced disease-free patient survival 
(Maelandsmo, Holm et al. 2003). Additionally, loss of nuclear ┚-catenin is associated with a 
reduction in patient life span (Bachmann, Straume et al. 2005). Alternatively, activation of 
┚-catenin is associated with reduced tumor cell proliferation (Chien, Moore et al. 2009). 
Taken together, these observations favor the notion that ┚-catenin plays a protective role in 
melanoma development. To date, however, neither how ┚-catenin develops such a role nor 
the mechanisms that lead to loss of ┚-catenin are fully understood. 
A possible explanation for these striking differences in comparison to colon cancer may be 
related to the type of Wnt ligand present. Analysis of melanocytic tumors reveals that levels 
of the Wnt ligands 3A and 5A are increased (Larue and Delmas 2006). However, these two 
Wnt ligands are thought to have opposite functions. In vitro assays show that Wnt 3A 
reduces cell proliferation in association with activation of the ┚-catenin pathway. Microarray 
analysis of 350 melanoma samples showed that high levels of ┚-catenin correlated with 
better patient prognosis, suggesting that activation of ┚-catenin pathway by Wnt 3A reduces 
melanoma cell proliferation (Chien, Moore et al. 2009). How activation of the Wnt/ ┚-
catenin pathway causes such effects in melanoma cells remains unclear, particularly since 
the opposite is seen in other cell types (Giles, van Es et al. 2003; Logan and Nusse 2004; 
Khan, Bradstock et al. 2007). 
Alternatively, Wnt 5A expression in melanomas correlates with tumor progression and 
metastasis (McDonald and Silver 2009), and Wnt 5A has been shown to increase melanoma 
cell migration (Dissanayake, Wade et al. 2007). Interestingly, these effects of Wnt 5A have 
been described both in in vitro and in vivo melanoma models (Dissanayake, Olkhanud et al. 
2008). In general, Wnt 5A enhances-melanoma cell migration but does so in a manner 
independent of the canonical Wnt/┚-catenin pathway (Dissanayake, Wade et al. 2007; 
Dissanayake, Olkhanud et al. 2008; O'Connell and Weeraratna 2009).  
Another important factor that contributes to changes in the Wnt/┚-catenin pathway is the 
tumor suppressor E-cadherin (Margineanu, Cotrutz et al. 2008; Wu, Lin et al. 2008). Mutations 
or loss of this cell-cell adhesion protein are associated with increases in ┚-catenin Tcf/Lef-
dependent transcription and cell proliferation (Berx, Nollet et al. 1998). Thus, loss of E-
cadherin generally correlates with poor patient prognosis. Moreover, changes in the 
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expression pattern of Cadherins are relevant. For instance, replacement of E-cadherin by N-
cadherin is linked to the epithelial-mesenquimal transition and acquisition of a more malignant 
cell phenotype (Gray-Schopfer, Wellbrock et al. 2007; Kreizenbeck, Berger et al. 2008) 
7. Caveolin-1  
Caveolins are a family of membrane-associated scaffolding proteins implicated in variety of 
functions in cells, including vesicle trafficking, cholesterol transport and regulation of signal 
transduction (Anderson 1998; Okamoto, Schlegel et al. 1998; Quest, Leyton et al. 2004). To 
date three major isoforms have been described in mammals, namely caveolin-1, -2 and -3 
(18-24 kDa). All three isoforms are encoded by distinct genes (Williams and Lisanti 2004). 
While caveolin-1 and -2 are fairly generically expressed, caveolin-3 presence is limited to 
muscle and glial cells (Okamoto, Schlegel et al. 1998; Razani, Schlegel et al. 2000; Williams 
and Lisanti 2004). Different variants have been described for caveolin-1 and -2 (Razani, 
Woodman et al. 2002; van Deurs, Roepstorff et al. 2003). 
Since caveolin-1 is the best characterized isoform, the discussion here will focus on this 
protein. Two variants referred to as caveolin-1┙ and-1┚ have been described that are 
generated by alternative initiation or splicing (Scherer, Tang et al. 1995; Kogo and Fujimoto 
2000; Kogo, Aiba et al. 2004). Caveolin-1┚ lacks the first 31 amino acids present in caveolin-
1┙. This region contains the amino acid tyrosine 14, which is phosphorylated by src family 
kinases (Cao, Courchesne et al. 2002; Labrecque, Nyalendo et al. 2004). Caveolin-1 assumes 
an unusual topology, whereby a central hydrophobic domain (residues 102-134) is thought 
to form a hairpin structure within the membrane (Figure 3). As a consequence, both the N-
terminal (residues 1-101) and C-terminal domain (residues 135-178) face the cytoplasm. A  
41-amino acid region in the N-terminal domain, as well as COOH-terminal elements are 
required for  the formation of caveolin-1 homo-oligomers. In the C-terminal segment, three 
palmitoylation sites are present at positions 133, 143 and 156 (Figure 3). 
Caveolin-1 is phosphorylated on tyrosine-14 in response to growth factors like insulin 
(Mastick, Brady et al. 1995; Mastick and Saltiel 1997; Lee, Volonte et al. 2000; Kimura, Mora 
et al. 2002) or EGF (Lee, Volonte et al. 2000; Orlichenko, Huang et al. 2006) and by 
extracellular stimuli including, UV, oxidative stress or hyperosmolarity (Li, Seitz et al. 1996; 
Volonte, Galbiati et al. 2001; Sanguinetti and Mastick 2003; Cao, Sanguinetti et al. 2004). 
These observations have implicated caveolin-1 and particularly phosphorylation on tyrosine 
14 in cellular stress responses. Consistent with this notion, caveolin-1 knockout mice have a 
reduced lifespan and are less resistant to partial hepatectomy (Park, Cohen et al. 2003; 
Fernandez, Albor et al. 2006). 
Caveolin-1 and phosphorylated caveolin-1 are also implicated in cell migration. A specific 
aminoacid sequence (aminoacids 46-55) is required for localization of the protein to the rear 
of migrating cells (Sun, Flynn et al. 2007; Sun, Liu et al. 2009) and such polarized 
distribution of caveolin-1 and associated cell signaling elements is considered important for 
directional migration of some cell types (Isshiki, Ando et al. 2002; Parat, Anand-Apte et al. 
2003; Beardsley, Fang et al. 2005). Although phosphorylation of caveolin-1 on tyrosine 14 
has been shown to favor migration via a process involving recruitment of the adaptor 
protein Grb7 (Lee, Volonte et al. 2000), the precise role of caveolin-1 in these events remains 
an issue of controversy. In part this is attributable to technical problems associated with the 
precise identification of phospho-caveolin-1 localization in migrating cells (Hill, Scherbakov 
et al. 2007).  
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Fig. 3. Caveolin-1 structure and caveolae morphology.  
A) Schematic showing the different domains present in caveolin-1 that permit interaction 
with other proteins and membranes. B) Caveolin-1 anchorage via the membrane insertion 
domain into regions enriched in sphingolipids and cholesterol. C) Caveolin-1 oligomerizes 
to generate the proteinaceous coat of caveolae, small invaginations (50-100 nm) of the 
plasma membrane. Additional proteins called cavins are also essential for the formation of 
these structures (not shown). 
Despite these issues, a large body of literature is available linking the expression of caveolin-
1 not only to enhanced migration but also metastasis of cancer cells. Likewise, caveolin-1 is 
implicated in development of the multi-drug resistant phenotype of aggressive cancer cells. 
All three characteristics of caveolin-1 mentioned, namely its participation in cellular stress 
responses and regeneration, migration and metastasis, as well as multi-drug resistance tend 
to favor the interpretation that caveolin-1 represents a protein whose presence is associated 
with tumor progression. Such evidence, however, has generated an intense discussion 
concerning the precise role of caveolin-1 in cancer, since also a large body of data is 
available suggesting that caveolin-1 functions as a tumor suppressor (see subsequent 
sections). A key objective in the remaining section of this chapter will be to highlight 
important aspects of this ongoing discussion and attempt to reconcile these different and 
opposing functions of caveolin-1 in a working model (see Figure 4). In doing so, we will 
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focus our attention mostly on studies dealing with the role of caveolin-1 in modulating the 
Wnt/┚-catenin pathway.  
8. Role of caveolin-1 as tumor suppressor: Inhibition of β-catenin-Tcf/Lef-
dependent gene expression 
Over the last 15 years, a large amount of data has become available associating the presence of 
caveolin-1 with tumor suppression. However, as will be discussed, the ability of caveolin-1 to 
act in this fashion depends on the cellular context. Thus, caveolin-1 should be considered a 
“conditional” tumor suppressor. In initial studies, oncogene-mediated transformation of 
NIH3T3 fibroblasts was shown to correlate with reduced caveolin-1 mRNA and protein levels, 
and re-expression of the protein was sufficient to revert cell transformation (Koleske, 
Baltimore et al. 1995; Engelman, Wykoff et al. 1997). Likewise selective loss of caveolin-1 
expression using an siRNA approach was sufficient to transform NIH3T3 fibroblasts (Galbiati, 
Volonte et al. 1998). Furthermore, caveolin-1 expression is reduced in a number of human 
tumors, including lung, mammary, colon and ovarian carcinomas, as well as osteosarcomas 
(Lee, Reimer et al. 1998; Racine, Belanger et al. 1999; Bender, Reymond et al. 2000; Wiechen, 
Diatchenko et al. 2001; Wiechen, Sers et al. 2001; Bender, Montoya et al. 2002; Ho, Huang et al. 
2002; Cantiani, Manara et al. 2007). Here too, re-expression of caveolin-1 frequently, but not 
always, reverts characteristics associated with the transformed phenotype (Yang, Truong et al. 
1998; Li, Yang et al. 2001; Tahir, Yang et al. 2001; Karam, Lotan et al. 2007; Yang, Addai et al. 
2007; Bartz, Zhou et al. 2008). More recently, decreased caveolin-1 levels have been reported 
for lymph node metastases from head and neck squamous cell carcinoma and restoration of 
caveolin-1 expression suppresses growth and metastasis (Zhang, Su et al. 2008). 
Despite the fact that caveolin-1 depletion in knockout mice does not lead to drastic 
changes in viability, it is now clear that caveolin-1 absence favors lung and mammary 
hyperplasia, angiogenesis, as well as carcinogen induced tumor formation in skin tissue 
(Drab, Verkade et al. 2001; Razani, Engelman et al. 2001; Capozza, Williams et al. 2003; 
Williams, Cheung et al. 2003). Also, increased mammary and intestinal stem cell 
proliferation is observed in caveolin-1 knockout mice and caveolin-1 was also shown to 
control neural stem cell proliferation (Jasmin, Yang et al. 2009). Finally, stromal 
expression of caveolin-1 in breast cancer predicts outcome, recurrence and survival, 
further highlighting its relevance as a potential therapeutic target (Sloan, Ciocca et al. 
2009; Witkiewicz, Dasgupta et al. 2009). Indeed, caveolin-1 mutation of P132L, which was 
previously linked to breast cancer (Hayashi, Matsuda et al. 2001), was recently 
demonstrated to predict recurrence and metastasis in an orthotopic mouse model 
(Bonuccelli, Casimiro et al. 2009). Taken together, these reports demonstrate that caveolin-
1 displays traits consistent with a role of the protein as a tumor suppressor. This ability of 
caveolin-1 has often been linked to inhibition of signalling events associated with cell 
survival and proliferation. However, it is important to note that alternative mechanisms 
have also been proposed. For a more detailed discussion of literature related to the tumor 
suppressor hypothesis, the interested reader is referred to additional reviews (Williams 
and Lisanti 2005; Quest, Gutierrez-Pajares et al. 2008).  
Initially, our entrance to the caveolin-1 field came with the demonstration that caveolin-1 
protein levels are reduced both in tumors from patients with colon cancer, as well as in 
colon adenocarcinoma cells and that caveolin-1 functions as a tumor suppressor in vivo upon 
re-expression in different colon adenocarcinoma cells (Bender, Reymond et al. 2000; Bender, 
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Montoya et al. 2002). Despite the ever-increasing abundance of signaling molecules 
available in the literature for regulation by caveolin-1, at the time relatively few were linked 
to specific transcriptional events. Thus, as one approach, we set out to compare, by 
microarray analysis, colon cancer cell lines expressing or not caveolin-1. Rather intriguingly, 
those studies identified in an initial screen the IAP protein survivin as one of the most 
strongly down-regulated targets at the transcriptional level (Torres, Tapia et al. 2006). This 
protein is of tremendous interest, since it is abundantly expressed in a variety of human 
tumors including lung, colon, breast, prostate, pancreatic, and gastric carcinoma, but is 
essentially absent in most normal tissues. Importantly, survivin expression in cancer cells is 
linked to tumor survival. These characteristics define survivin as a tumor specific antigen 
(Li, Ambrosini et al. 1998; Reed 2001; Altieri 2003).  
The mayor challenge then was identifying a mechanism that permitted connecting events 
thought to occur at the plasma membrane with transcription in the nucleus. Given the 
importance of canonical Wnt signaling in colon cancer, this pathway became an attractive 
potential caveolin-1 target. This possibility was further substantiated by reports showing on 
the one hand that caveolin-1 expression prevented transcription of cyclinD1 by sequestering 
┚-catenin (Hulit, Bash et al. 2000) and on the other that survivin is a ┚-catenin/Tcf/lef target 
gene (Kolligs, Bommer et al. 2002). With this in mind, we then established that caveolin-1 
controled survivin expression by sequestering ┚-catenin to the plasma membrane (Torres, 
Tapia et al. 2006) and subsequently that this ability required the expression of E-cadherin in 
both colon cancer and melanoma cell lines (Torres, Tapia et al. 2007). Finally, evidence was 
obtained showing that caveolin-1 regulates in a similar fashion also the expression of 
cyclooxygenase-2 (COX2; (Rodriguez, Tapia et al. 2009). 
Since loss of E-cadherin is frequently observed in human epithelial tumors (Cavallaro and 
Christofori 2004), our studies suggest that the combined loss of caveolin-1 and E-cadherin in 
epithelial cells is likely to promote increased expression of genes relevant to 
epithelial-mesenchymal transition, loss of cell-cell contacts and cell transformation. Perhaps 
even more importantly, they provide mechanistic insight to how caveolin-1-specific 
suppression of genes associated with its role as a tumor suppressor becomes “conditional”, 
that is dependent on the cellular context (Torres, Tapia et al. 2007; Quest, Gutierrez-Pajares 
et al. 2008). Interestingly, this ability of caveolin-1 is not only limited by the proteins present 
within cells expressing caveolin-1, but also by factors present in the cellular medium. In 
particular, caveolin-1 expression was shown to limit PGE2 accumulation in the culture 
media of HEK293T, DLD-1 and HT29 cells. Alternatively, supplementation of media with 
PGE2 disrupted caveolin-1 complexes responsible for sequestration of ┚-catenin to the 
plasma membrane (Rodriguez, Tapia et al. 2009).  
Despite the abundance of evidence summarized previously indicating that caveolin-1 
functions as a tumor suppressor, there is also evidence suggesting a radically different, even 
opposite role for caveolin-1. Specifically, caveolin-1 is known to promote tumor formation 
and presence is correlated with poor prognosis and survival in prostate cancer. Indeed, the 
expression of caveolin-1 reportedly increases in primary tumors from prostate (Yang, 
Truong et al. 1998) and certain leukemia derived cell lines (Hatanaka, Maeda et al. 1998). 
Also, in prostate cancer cells caveolin-1 presence increases tumor growth and the incidence 
of metastasis (Li, Yang et al. 2001; Tahir, Yang et al. 2001; Karam, Lotan et al. 2007; Bartz, 
Zhou et al. 2008). Increased caveolin-1 expression in tumor samples is not restricted to cases, 
like the prostate, where normal tissues have low relative caveolin-1 levels, since increased 
expression was also reported in tumor models where initial caveolin-1 loss is observed, such 
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as colon (Bender, Reymond et al. 2000) and breast cancer (Fiucci, Ravid et al. 2002; Garcia, 
Dales et al. 2007; Savage, Lambros et al. 2007).  
In most of these cases, the available data argue for a strong positive correlation between 
expression of caveolin-1, metastasis and multidrug resistance (Lavie, Fiucci et al. 1998; Lavie 
and Liscovitch 2000; Garcia, Dales et al. 2007). Moreover, studies in samples derived from 
esophageal squamous cell carcinoma (Ando, Ishiguro et al. 2007), small cell lung carcinomas 
(Ho, Huang et al. 2002), colon cancer cells with elevated metastatic potential ((Bender, 
Reymond et al. 2000), see below) and gastric cancer (Burgermeister, Tencer et al. 2003), 
revealed that caveolin-1 expression correlates with poor patient prognosis. Furthermore, 
caveolin-1 is also overexpressed in nasopharyngeal carcinoma and protein levels correlate 
there with poor prognosis, enhanced tumor cell migration and metastasis (Du, Hu et al. 
2009). Finally, caveolin-1 was recently associated with tumor progression in a panel of 
melanoma cell lines, since increased expression correlated with enhanced proliferation, cell 
migration and tumorigenicity (Felicetti, Parolini et al. 2009). 
9. Caveolin-1 function as a promoter of metastasis: The role of 
phosphorylation on tyrosine-14 
A variety of potential mechanisms have been invoked to explain how caveolin-1 presence may 
favor tumor progression. For example, in prostate cancer cells, increased caveolin-1 levels 
were found to favor growth factor release and regulation by a positive feedback loop that 
enhances tumor cell invasiveness (Li, Ren et al. 2009) and VEGF-associated pro-angiogenic 
signaling (Tahir, Park et al. 2009). Futhermore, Caveolin-1 is located on prostasomes secreted 
by prostate cancer cells (Llorente, de Marco et al. 2004) and the presence of antibodies against 
caveolin-1 in blood plasma decreased prostate cancer cell metastasis in animal models 
(Watanabe, Yang et al. 2009). In breast cancer cells, caveolin-1 was recently shown to associate 
with type 1 matrix metalloproteinase and thereby promote invadopodia formation, as well as 
matrix degradation, both of which favor invasiveness (Yamaguchi, Takeo et al. 2009). Also, 
caveolin-1 enhanced hepatocellular carcinoma cell motility and invasiveness is associated with 
augmented metalloproteinase expression and secretion, together with down-regulation of E-
cadherin (Cokakli, Erdal et al. 2009). Alternatively, re-expression of caveolin-1 in lung 
adenocarcinoma cells is sufficient to promote filopodia formation, cell migration and 
metastatic potential of these cells (Ho, Huang et al. 2002). Thus, as so often, the alterations 
observed due to the presence of caveolin-1 depend on the model under study. However, all 
the aforementioned observations have in common that caveolin-1 promotes traits associated 
with increased malignancy of cancer cells. 
Successful tumor cell metastasis to distant sites requires the acquisition of multiple traits, 
including the ability to migrate. Interestingly, caveolin-1 is required for cell polarization and 
migration in two and three dimensions (Parat, Anand-Apte et al. 2003; Beardsley, Fang et al. 
2005; Santilman, Baran et al. 2007; Yamaguchi, Takeo et al. 2009). Additionally, caveolin-1 
regulates the small GTPases Rho and Rac, which are required for actin dynamics, cell 
polarization and directional migration (del Pozo, Balasubramanian et al. 2005; Grande-
Garcia, Echarri et al. 2007; Grande-Garcia and del Pozo 2008). Furthermore, phosphorylation 
of caveolin-1 on tyrosine-14 favors cell migration (Grande-Garcia, Echarri et al. 2007) and 
anchorage-independent growth via the adaptor protein Grb7 (Lee, Volonte et al. 2000). 
Thus, in addition to its role as a tumor suppressor, caveolin-1 clearly also displays 
characteristics of a protein that promotes cell migration and metastasis. 
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Many explanations for such variations in function exist. One possibility is that the role of 
caveolin-1  depends on the cellular environment and that tumor suppressor activity is 
developed in systems where negative signalling occurs downstream of caveolin-1. 
Alternatively, when presence of the protein is associated with more aggressive tumor 
behavior, positive caveolin-1 mediated signalling is likely to be more important (reviewed in 
(Quest, Leyton et al. 2004; Quest, Gutierrez-Pajares et al. 2008)). A fundamental problem here 
is that direct comparisons are difficult, since these distinct characteristics were observed in 
different experimental settings and cell models. Ideally, to begin to test the aforementioned 
working hypothesis and identify molecular features of caveolin-1 that contribute to one or the 
other behavioral pattern, an approach that permits evaluation of these two characteristics in 
the same cell/animal model would be required. In this respect, some recent results from our 
laboratory suggest that melanomas may represent an interesting model. 
 
 
 
Fig. 4. Dual role of caveolin-1 in cancer: Representative profiles of caveolin-1 expression in 
different types of human cancer cells. 
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Two profiles of caveolin-1 expression appear to prevail in human cancer (Figure 4). In the 
first case, caveolin-1 expression is as follows: i) caveolin-1 is expressed in normal tissue. ii) 
During the development of cancer, caveolin-1 levels decline. iii) In later stages caveolin-1 re-
expression occurs. Examples here include lung, colon and breast cancer. The second 
possibility is: i) Essentially, caveolin-1 is not expressed in normal tissue. ii) Caveolin-1 
expression increases with tumor progression. The typical example here is prostate cancer. 
As, indicated, in many cancer cell types expression of caveolin-1 is associated with enhanced 
migratory  capacity and multidrug resistance. How changes in caveolin-1 expression relate 
to melanoma development remain unclear. These characteristics are summarized again in 
the table (Figure 4). Additionally, the effects of loss of caveolin-1 expression in different 
tissues of knock-out mice are mentioned, as well as the consequences of either over-
expressing or down-regulating caveolin-1 in tumor cells. 
10. Caveolin-1 in melanoma  
Relatively little information is available concerning the role of caveolin-1 in melanomas. 
Early reports focussed on studying the relationship between this protein and 
glycosphingolipids, which are important constituents of membrane microdomains referred 
to as “glycolipid-enriched membranes”, “detergent-insoluble microdomains” (DIMs) or 
simply “membrane rafts” because of their flotation behaviour on sucrose gradients 
following centrifugation. Depending on whether or not caveolin-1 is associated with such 
membrane rafts, these may become detectable as 50-100 nm invaginations of the membrane 
called caveolae. Both membrane rafts and caveolae have received considerable attention due 
to their participation in a variety of cellular processes, including endocytosis, cholesterol 
transport, micro-organism infection and signal transduction. A detailed discussion of these 
aspects can be found elsewhere (Quest et al., 2004; 2008). Here, they are relevant because of 
their reported role in the regulation of signals associated with the development of malignant 
properties in cancer cells. For instance, in B16 mouse melanoma cells, a GM3-enriched 
membrane subdomain implicated in adhesion and migration was found to contain a 
number of relevant signaling molecules, including c-Src, FAK, and RhoA. This GM3 
enriched “glycosphingolipid signaling domain” however does not contain caveolin-1 and 
appears to represent a functionally distinct identity from caveolin-1 and cholesterol-
enriched microdomains in these cells  (Iwabuchi et al 1998).  
Acidic glycosphingolipids also play an important role in tumor biology and particularly 
GD3 expression is increased in almost all malignant melanomas and melanoma cell lines. 
In human melanoma cells, GD3 presence is associated with enhanced tyrosine 
phosphorylation of the two adaptor molecules p130Cas and paxillin. In SK-MEL-28 
human melanoma cells, GD3 accumulates at the leading edge together with the 
aforementioned adaptor molecules and is thought to promote migration. In cells 
expressing caveolin-1, GD3 becomes homogeneously distributed in the membrane, rather 
than concentrated in specific regions. Hence, caveolin-1 is suggested to function as a 
tumor suppressor in melanoma cells by disrupting GD3-mediated malignant signaling 
(Nakashima, Hamamura et al. 2007).  
Alternatively, for a non-cutaneous, retinal melanoma, increased caveolin-1 expression was 
associated with enhanced malignancy. Previous reports had documented low levels of 
caveolin-1 expression in different cell types of normal murine retinal tissue. Essentially this 
was corroborated in human tissue and, additionally, the level of expression of caveolin-1 
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was shown to increase in retinal melanoma cells (Berta, Kiss et al. 2007). An even more 
recent study identified exosomes in the plasma of melanoma patients, with high levels of 
caveolin-1. Exosomes are small vesicle secreted by both normal and tumoral cells. In this 
particular case, they were attributed immunosuppressive effects and associated with 
malignant tumor progression (Logozzi, De Milito et al. 2009). This study suggests that 
mechanisms similar to those already mentioned for prostate cancer may be relevant to 
caveolin-1 function in melanoma metastasis.  
The notion that caveolin-1 presence may favor metastasis is supported by additional studies. 
Felicetti and co-workers proposed that caveolin-1 expression is associated with increased 
metastatic potential in different human melanoma cell lines. Specifically, caveolin-1 
expression was increased using retroviral vectors in human melanoma cell lines. For the 
WM983A melanoma cell line, caveolin-1 increased cell proliferation, anchorage-independent 
growth, migration and invasion. Also, caveolin-1 down-regulation in metastatic caveolin-1-
expressing melanomas reduces their proliferation, as well as their tumorigenicity (Felicetti, 
Parolini et al. 2009).  Rather surprisingly, another recent report indicates that caveolin-1 
blocks metastasis of malignant melanomas in a murine model (Trimmer, Whitaker-Menezes 
et al. 2010). Caveolin-1 has previously been shown to down-regulate survivin expression by 
sequestering ┚-catenin to the plasma membrane and reducing ┚-catenin-Tcf/Lef dependent 
transcription (Torres, Tapia et al. 2006). To do so, cells must express E-cadherin. However, 
E-cadherin is frequently silenced in melanomas and downregulation of this protein is 
considered one of the possible causes of melanoma progression and metastasis. Indeed, 
B16F10 cells do not express E-cadherin. Accordingly, E-cadherin re-expression in B16F10 
murine melanoma cell line restored the ability of caveolin-1 to reduce cell proliferation and 
increase apoptosis by repressing survivin (Torres, Tapia et al. 2007).  
Once again these findings highlight the apparent ambiguity of caveolin-1 function in 
melanomas and clearly more studies are warranted. As mentioned previously, an ideal 
experimental system would permit observing the role of caveolin-1 as a tumor suppressor 
and promoter of metastasis in the same cell/animal model.  
11. Tumor formation assays in mouse melanoma models 
Currently available models for the study of melanomas include: i) Xeno-transplantation 
models using genetically modified animals. One frequently employed possibility here are 
immunosuppressed animals that can be challenged with cells of another species. (ii) 
Syngeneic transplantation models. In this case, melanoma cells are derived from the same 
host so that immunological responses are avoided. Some examples here include 
Harding-Passey melanoma in BALB/c x DBA/2F1 mice, the Cloudman S91 melanoma in 
DBA/2 mice and the B16 melanoma in C57BL/6 mice. (iii) Genetically modified animals 
that develop spontaneous melanomas. Examples here include mouse lines expressing 
known oncogenes, such as Ret or mutant forms of Ras and Raf under the control of 
ubiquitous or tissue-specific promoters. Such mice develop melanocytic hyperplasia, retinal 
pigmented epithelial tumors and melanomas (Becker, Houben et al. 2010). 
11.1 Syngeneic B16-F10 murine melanoma model 
In our laboratory, the effects of caveolin-1 have been evaluated using two in vivo model 
systems, a xeno-transplantation model for HT29 and DLD-1 human colon adenocarcinoma 
cell lines in nude mice (Bender, Reymond et al. 2000) and the syngeneic B16 murine 
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melanoma model in C57BL6 mice (Nicolson, Brunson et al. 1978). Both models serve well to 
assess the ability of a protein like caveolin-1 to function as a tumor suppressor or promoter 
upon subcutaneous injection of the tumor cells. However, a major advantage of the latter 
model is that the behaviour of cells injected into the tail vein can also be readily evaluated. 
Since these cells are pigmented, dissemination throughout the body or specifically to the 
lung can be quantified for cells independent of whether they have been selected for homing 
or not (B16F10 versus B16F0 cells). Additionally, this model is closer to the situation in 
human patients because the tumors develop from cells in syngeneic mice with a fully 
functional immune system. 
The schematic below (Figure 5) summarizes the origin of B16F0 cells (poorly metastatic) and 
how B16F10 cells (highly metastatic) were obtained by repetitive cycles of  injection into the 
tail vein and recovery from the lung. Moreover, the figure highlights how the behaviour of 
such cells can be evaluated in tumor formation and metastasis assays. 
 
 
 
Fig. 5. Generation of B16F0 and  B16-F10 cells (Nicolson, Brunson et al. 1978).  
The parent tumor cell population of B16-F0 cells was isolated from a spontaneous melanoma 
in C57BL6 mice. These cells were then selected for their ability to colonize the lung 
following intravenous injection. To that end, B16-F0 cells were injected into the tail vein of 
C57BL/6 mice. Cells that formed tumors in the lung were expanded in culture and then 
injected again into the tail vein. This process was repeated ten times and the resulting 
population is referred to as B16-F10 cells. These cells behave very differently depending on 
the microenvironment. When B16-F10 cells are injected sub-cutaneously they form defined,  
palpable tumors. Alternatively, when injected intravenously these cells colonize the lung to 
form well defined black melanocytic nodules. See also figures 6 and 7, respectively. 
11.2 Tumour formation in the B16F10 melanoma model 
To study the ambiguity of caveolin-1 function, B16-F10 cells transfected or not with a 
plasmid (placIOP) permitting IPTG-inducible expression of caveolin-1 (plaIOP(cav-1)) were 
employed. These cells have been described previously (Torres, Tapia et al. 2007). The in vivo 
effect of the caveolin-1 expression in B16-F10 melanoma cells was evaluated by 
subcutaneous injection into of the flanks of mice. Appearance of tumors was monitored by 
palpitation and in initial experiments confirmed by histopathological analysis (Figure 6). 
Histological sections revealed that the tumors were composed entirely of proliferating 
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melanoma cells, whereas extracellular matrix, blood vessels and the stroma were largely 
confined to the tumor perifery. Hence, the tumors observed in this model system are rather 
soft and gelatinous, making manipulation for immunohistochemical analysis more difficult 
(Figure 6). Mice were monitored for 7 to 30 days after the challenge with tumor cells. As 
shown, our preliminary results using this syngeneic murine melanoma model indicated that 
caveolin-1 was able to suppress tumor formation in vivo (see Fig. 6A and 6B).  
 
 
 
Fig. 6. Characterization of subcutaneous tumors.  
C57BL/6 mice were inoculated with B16-F10 (mock) and B16-F10 (cav-1) cells on the left and 
right side of the animal, respectively. When the tumors of B16-F10(mock) cells reached the 
bioethically permitted limit the animals were sacrificed and the tumors were fixed in 
paraformaldehyde, embedded in paraffin, sectioned and stained with hematoxylin and 
eosin for histological analysis. A) Mouse inoculated with B16-F10(mock) and B16-F10(cav-1) 
cells injected into the left and right flank, respectively. B) Dissected tumors from mouse 
injected with cells as indicated in A. White arrows indicate external blood vessels. Yellow 
arrows highlight the tumor overlying serous tissue. C) Scheme showing how stroma 
support tissue surrounds the tumor. D) Histological section of a subcutaneous melanoma 
tumor, where the stroma and blood vessels surround the homogeneous tumor mass. E) 
Histological section of another subcutaneous tumor. White arrow: blood vessel located 
outside of the tumor; yellow arrow: stromal tissue. 
12. Metastasis assays 
To date, studies that employ the B16F10 model of lung metastasis generally quantify the 
metastastic nodules that are apparent at the lung surface (Figure 7). However, evidence in 
the literature indicates that this mode of quantification probably sub-estimates the actual 
extent of metastasis.  Specifically, for B16F10 cells it is known that the cell adhesion 
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molecule Lu-ECAM-1 plays a fundamental role in retention of these cells in the lung. This 
molecule is present to some extent in venes of the parenchyma, but is strongly expressed 
particularly in sub-pleural and pleural venes, as well as in large venes of the lung and 
venes of the mesenchyma (Zhu, Cheng et al. 1991). The sites of expression Lu-ECAM-1 are 
entirely consistent with the distribution of melanomas we observed upon dissection of the 
lung. Moreover, the extent of lung metastasis observed by freezing the lungs of 
experimental animals, separating melanoma from normal tissue and then weighing both 
yielded results that were distinct from those obtained by simply counting nodules at the 
surface, as was reported (Trimmer, Whitaker-Menezes et al. 2010). In our hands, 
preliminary experiments indicated that the approach of actually quantifying lung tumor 
mass was far superior in detecting lung metastasis for B16 F10 cells expressing caveolin-1. 
Results obtained in this manner with B16-F10 cells clearly indicate that augmented 
caveolin-1 expression levels enhanced the metastatic potential of these melanoma cells 
when injected intravenously into animals. Taken together, the results discussed here 
suggest that the B16F10/C57BL6 model represents an ideal experimental system to 
identify molecular traits in caveolin-1 associated with its role as a tumor suppressor and 
promoter of metastasis. 
 
 
 
Fig. 7. Lung metastases.  
B16-F10 cells were cultured in 100 mm plates for 48 h. Control mice were inoculated 
intravenously with saline solution (left panel) and the other group of mice were inoculated 
with 200,000 B16-F10 cells in 500 l of saline solution (right panel). On day  21 post-injection, 
the animals were sacrificed, organs were removed and  necropsied to identify melanocytic 
nodules. The lungs shown were fixed in Feketes buffer for 48 h. Arrowheads indicate 
nodules. 
13. The caveolin-1 dilema: Summary and outlook 
The data summarized here reinforce the notion that caveolin-1 potentially plays a dual role 
in melanoma development, as has been described for other cancers (reviewed in (Quest, 
Leyton et al. 2004; Quest, Gutierrez-Pajares et al. 2008)). The ambiguity of caveolin-1 
function is perhaps best reconciled by the view portrayed in Figure 4. Colon cancer is an 
example where initial loss of caveolin-1 is followed by re-expression at later stages. If 
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caveolin-1 is re-expressed at early stages, it develops traits consistent with a role as a tumor 
suppressor. Regulation of the Wnt signaling pathway is one possibly relevant mechanism 
discussed here, although several more are likely to exist. During tumor progression, the 
cellular context changes, since expression of a large number of proteins is altered. One such 
possibility we eluded to is the loss of E-cadherin. However, extracellular components, such 
as PGE2 are also relevant. Hence, both “intracellular” and also “extracellular” changes 
define caveolin-1 function in a cell. When then later in tumor progression caveolin-1 
expression is triggered by as yet poorly defined mechanisms, the protein no longer 
encounters conditions that permit function as a tumor suppressor, and for instance 
suppression of -catenin-dependent transcription. Instead, characteristics associated with 
malignant cell behavior, including increased cell migration, may prevail. For prostate 
cancer, the situation is different because caveolin-1 is not expressed in normal tissue. At this 
point, it is still not clear which of these examples is closest to the situation in melanomas. 
However, particularly the studies by Felicetti and co-workers (Felicetti, Parolini et al. 2009) 
indicate that prostate may represent a more appropriate comparison. However, it should be 
noted that loss of E-cadherin represents a crucial step towards metastasis in the 
development of melanomas. Bearing this in mind, one may suspect that augmented 
expression of caveolin-1 in later stages of melanoma development will promote the 
acquisition of a more malignant phenotype in these cells. The availability of an experimental 
model where both characteristics of the protein can be detected and analyzed in vivo, now 
permit defining the molecular traits associated with tumor suppression and enhanced 
metastasis. With such insight at hand, we may anticipate the design and use of successful 
caveolin-1-based strategies in the treatment of melanoma. 
14. Acknowledgements 
The work was supported by the FONDECYT-FONDAP grant #15010006, FONDECYT grant 
#1090071 (to A.F.G.Q). 
15. Abbreviations 
AA, arachidonic acid; APC, adenomatous polyposis coli; CSD, caveolin scaffolding domain; 
GSK3┚, glycogen synthase kinase; IAP, inhibitor of apoptosis; MDR, multidrug resistance; 
NSAIDs, non-steroidal anti-inflammatory drugs; PCP, planar cell polarity; PGE2, 
prostaglandin E2; PGH2, prostaglandin H2; Tcf/Lef, T cell factor/lymphoid enhancer 
binding factor; SCF, Skp1-Cul1-F-box-protein. 
16. References 
Altieri, D. C. (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3(1): 
46-54. 
Anderson, R. G. (1998). The caveolae membrane system. Annu Rev Biochem 67: 199-225. 
Ando, T., H. Ishiguro, et al. (2007). The overexpression of caveolin-1 and caveolin-2 
correlates with a poor prognosis and tumor progression in esophageal squamous 
cell carcinoma. Oncol Rep 18(3): 601-609. 
www.intechopen.com
 Advances in Malignant Melanoma – Clinical and Research Perspectives 206 
Bachmann, I. M., O. Straume, et al. (2005). Importance of P-cadherin, beta-catenin, and 
Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous 
melanoma. Clin Cancer Res 11(24 Pt 1): 8606-8614. 
Bartz, R., J. Zhou, et al. (2008). Caveolin-1 secreting LNCaP cells induce tumor growth of 
caveolin-1 negative LNCaP cells in vivo. Int J Cancer 122(3): 520-525. 
Beardsley, A., K. Fang, et al. (2005). Loss of caveolin-1 polarity impedes endothelial cell 
polarization and directional movement. J Biol Chem 280(5): 3541-3547. 
Becker, J. C., R. Houben, et al. (2010). Mouse models for melanoma: a personal perspective. 
Exp Dermatol 19(2): 157-164. 
Bender, F., M. Montoya, et al. (2002). Caveolae and caveolae-like membrane domains in 
cellular signaling and disease: identification of downstream targets for the tumor 
suppressor protein caveolin-1. Biol Res 35(2): 151-167. 
Bender, F. C., M. A. Reymond, et al. (2000). Caveolin-1 levels are down-regulated in human 
colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines 
reduces cell tumorigenicity. Cancer Res 60(20): 5870-5878. 
Berta, A. I., A. L. Kiss, et al. (2007). Different caveolin isoforms in the retina of melanoma 
malignum affected human eye. Mol Vis 13: 881-886. 
Berx, G., F. Nollet, et al. (1998). Dysregulation of the E-cadherin/catenin complex by 
irreversible mutations in human carcinomas. Cell Adhes Commun 6(2-3): 171-
184. 
Bienz, M. and H. Clevers (2000). Linking colorectal cancer to Wnt signaling. Cell 103(2): 311-
320. 
Bonuccelli, G., M. C. Casimiro, et al. (2009). Caveolin-1 (P132L), a common breast cancer 
mutation, confers mammary cell invasiveness and defines a novel stem 
cell/metastasis-associated gene signature. Am J Pathol 174(5): 1650-1662. 
Brembeck, F. H., M. Rosario, et al. (2006). Balancing cell adhesion and Wnt signaling, the key 
role of beta-catenin. Curr Opin Genet Dev 16(1): 51-59. 
Burgermeister, E., L. Tencer, et al. (2003). Peroxisome proliferator-activated receptor-gamma 
upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. 
Oncogene 22(25): 3888-3900. 
Cantiani, L., M. C. Manara, et al. (2007). Caveolin-1 reduces osteosarcoma metastases by 
inhibiting c-Src activity and met signaling. Cancer Res 67(16): 7675-7685. 
Cao, H., W. E. Courchesne, et al. (2002). A phosphotyrosine-dependent protein interaction 
screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment 
of C-terminal Src kinase. J Biol Chem 277(11): 8771-8774. 
Cao, H., A. R. Sanguinetti, et al. (2004). Oxidative stress activates both Src-kinases and their 
negative regulator Csk and induces phosphorylation of two targeting proteins for 
Csk: caveolin-1 and paxillin. Exp Cell Res 294(1): 159-171. 
Capozza, F., T. M. Williams, et al. (2003). Absence of caveolin-1 sensitizes mouse skin to 
carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 
162(6): 2029-2039. 
Cavallaro, U. and G. Christofori (2004). Cell adhesion and signalling by cadherins and Ig-
CAMs in cancer. Nat Rev Cancer 4(2): 118-132. 
www.intechopen.com
 Caveolin-1 in Melanoma Progression 207 
Cokakli, M., E. Erdal, et al. (2009). Differential expression of Caveolin-1 in hepatocellular 
carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer 
9: 65. 
Cheli, Y., M. Ohanna, et al. Fifteen-year quest for microphthalmia-associated transcription 
factor target genes. Pigment Cell Melanoma Res 23(1): 27-40. 
Chien, A. J., E. C. Moore, et al. (2009). Activated Wnt/beta-catenin signaling in melanoma is 
associated with decreased proliferation in patient tumors and a murine melanoma 
model. Proc Natl Acad Sci U S A 106(4): 1193-1198. 
De Panfilis, G., D. Ferrari, et al. (2009). Cytoplasmic beta-catenin is lacking in a subset of 
melanoma-associated naevi, but is detectable in naevus-associated melanomas: 
potential implications for melanoma tumorigenesis? Br J Dermatol 160(3): 600-
608. 
del Pozo, M. A., N. Balasubramanian, et al. (2005). Phospho-caveolin-1 mediates integrin-
regulated membrane domain internalization. Nat Cell Biol 7(9): 901-908. 
Dissanayake, S. K., P. B. Olkhanud, et al. (2008). Wnt5A regulates expression of tumor-
associated antigens in melanoma via changes in signal transducers and activators 
of transcription 3 phosphorylation. Cancer Res 68(24): 10205-10214. 
Dissanayake, S. K., M. Wade, et al. (2007). The Wnt5A/protein kinase C pathway mediates 
motility in melanoma cells via the inhibition of metastasis suppressors and 
initiation of an epithelial to mesenchymal transition. J Biol Chem 282(23): 17259-
17271. 
Drab, M., P. Verkade, et al. (2001). Loss of caveolae, vascular dysfunction, and pulmonary 
defects in caveolin-1 gene-disrupted mice. Science 293(5539): 2449-2452. 
Du, Z. M., C. F. Hu, et al. (2009). Upregulation of caveolin-1 and CD147 expression in 
nasopharyngeal carcinoma enhanced tumor cell migration and correlated with 
poor prognosis of the patients. Int J Cancer 125(8): 1832-1841. 
Engelman, J. A., C. C. Wykoff, et al. (1997). Recombinant expression of caveolin-1 in 
oncogenically transformed cells abrogates anchorage-independent growth. J Biol 
Chem 272(26): 16374-16381. 
Felicetti, F., I. Parolini, et al. (2009). Caveolin-1 tumor-promoting role in human melanoma. 
Int J Cancer 125(7): 1514-1522. 
Fernandez, M. A., C. Albor, et al. (2006). Caveolin-1 is essential for liver regeneration. Science 
313(5793): 1628-1632. 
Fiucci, G., D. Ravid, et al. (2002). Caveolin-1 inhibits anchorage-independent growth, 
anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21(15): 
2365-2375. 
Galbiati, F., D. Volonte, et al. (1998). Targeted downregulation of caveolin-1 is sufficient to 
drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. Embo 
J 17(22): 6633-6648. 
Garcia, S., J. P. Dales, et al. (2007). Poor prognosis in breast carcinomas correlates with 
increased expression of targetable CD146 and c-Met and with proteomic basal-like 
phenotype. Hum Pathol 38(6): 830-841. 
www.intechopen.com
 Advances in Malignant Melanoma – Clinical and Research Perspectives 208 
Garraway, L. A., H. R. Widlund, et al. (2005). Integrative genomic analyses identify MITF as 
a lineage survival oncogene amplified in malignant melanoma. Nature 436(7047): 
117-122. 
Giles, R. H., J. H. van Es, et al. (2003). Caught up in a Wnt storm: Wnt signaling in cancer. 
Biochim Biophys Acta 1653(1): 1-24. 
Gottardi, C. J., E. Wong, et al. (2001). E-cadherin suppresses cellular transformation by 
inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol 
153(5): 1049-1060. 
Grande-Garcia, A. and M. A. del Pozo (2008). Caveolin-1 in cell polarization and directional 
migration. Eur J Cell Biol 87(8-9): 641-647. 
Grande-Garcia, A., A. Echarri, et al. (2007). Caveolin-1 regulates cell polarization and 
directional migration through Src kinase and Rho GTPases. J Cell Biol 177(4): 683-
694. 
Gray-Schopfer, V., C. Wellbrock, et al. (2007). Melanoma biology and new targeted therapy. 
Nature 445(7130): 851-857. 
Haertel-Wiesmann, M., Y. Liang, et al. (2000). Regulation of cyclooxygenase-2 and periostin 
by Wnt-3 in mouse mammary epithelial cells. J Biol Chem 275(41): 32046-32051. 
Hajra, K. M. and E. R. Fearon (2002). Cadherin and catenin alterations in human cancer. 
Genes Chromosomes Cancer 34(3): 255-268. 
Hanahan, D. and R. A. Weinberg (2000). The hallmarks of cancer. Cell 100(1): 57-70. 
Hanahan, D. and R. A. Weinberg (2011). Hallmarks of cancer: the next generation. Cell 
144(5): 646-674. 
Hatanaka, M., T. Maeda, et al. (1998). Expression of caveolin-1 in human T cell leukemia cell 
lines. Biochem Biophys Res Commun 253(2): 382-387. 
Hayashi, K., S. Matsuda, et al. (2001). Invasion activating caveolin-1 mutation in human 
scirrhous breast cancers. Cancer Res 61(6): 2361-2364. 
He, T. C., A. B. Sparks, et al. (1998). Identification of c-MYC as a target of the APC pathway. 
Science 281(5382): 1509-1512. 
Heeg-Truesdell, E. and C. LaBonne (2006). Wnt signaling: a shaggy dogma tale. Curr Biol 
16(2): R62-64. 
Henderson, B. R. and F. Fagotto (2002). The ins and outs of APC and beta-catenin nuclear 
transport. EMBO Rep 3(9): 834-839. 
Hill, M. M., N. Scherbakov, et al. (2007). Reassessing the role of phosphocaveolin-1 in cell 
adhesion and migration. Traffic 8(12): 1695-1705. 
Ho, C. C., P. H. Huang, et al. (2002). Up-regulated caveolin-1 accentuates the metastasis 
capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 
161(5): 1647-1656. 
Ho, C. C., P. H. Huang, et al. (2002). Up-regulated caveolin-1 accentuates the metastasis 
capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 
161(5): 1647-1656. 
Huang, H. and X. He (2008). Wnt/beta-catenin signaling: new (and old) players and new 
insights. Curr Opin Cell Biol 20(2): 119-125. 
Hulit, J., T. Bash, et al. (2000). The cyclin D1 gene is transcriptionally repressed by caveolin-
1. J Biol Chem 275(28): 21203-21209. 
www.intechopen.com
 Caveolin-1 in Melanoma Progression 209 
Isshiki, M., J. Ando, et al. (2002). Sites of Ca(2+) wave initiation move with caveolae to the 
trailing edge of migrating cells. J Cell Sci 115(Pt 3): 475-484. 
Jasmin, J. F., M. Yang, et al. (2009). Genetic ablation of caveolin-1 increases neural stem cell 
proliferation in the subventricular zone (SVZ) of the adult mouse brain. Cell Cycle 
8(23): 3978-3983. 
Jeanes, A., C. J. Gottardi, et al. (2008). Cadherins and cancer: how does cadherin dysfunction 
promote tumor progression? Oncogene 27(55): 6920-6929. 
Kageshita, T., C. V. Hamby, et al. (2001). Loss of beta-catenin expression associated with 
disease progression in malignant melanoma. Br J Dermatol 145(2): 210-216. 
Karam, J. A., Y. Lotan, et al. (2007). Caveolin-1 overexpression is associated with aggressive 
prostate cancer recurrence. Prostate 67(6): 614-622. 
Khan, N. I., K. F. Bradstock, et al. (2007). Activation of Wnt/beta-catenin pathway mediates 
growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J 
Haematol 138(3): 338-348. 
Kim, P. J., J. Plescia, et al. (2003). Survivin and molecular pathogenesis of colorectal cancer. 
Lancet 362(9379): 205-209. 
Kimelman, D. and W. Xu (2006). beta-catenin destruction complex: insights and questions 
from a structural perspective. Oncogene 25(57): 7482-7491. 
Kimura, A., S. Mora, et al. (2002). The insulin receptor catalyzes the tyrosine 
phosphorylation of caveolin-1. J Biol Chem 277(33): 30153-30158. 
Klaus, A. and W. Birchmeier (2008). Wnt signalling and its impact on development and 
cancer. Nat Rev Cancer 8(5): 387-398. 
Kogo, H., T. Aiba, et al. (2004). Cell type-specific occurrence of caveolin-1alpha and -
1beta in the lung caused by expression of distinct mRNAs. J Biol Chem 279(24): 
25574-25581. 
Kogo, H. and T. Fujimoto (2000). Caveolin-1 isoforms are encoded by distinct mRNAs. 
Identification of mouse caveolin-1 mRNA variants caused by alternative 
transcription initiation and splicing. FEBS Lett 465(2-3): 119-123. 
Koleske, A. J., D. Baltimore, et al. (1995). Reduction of caveolin and caveolae in 
oncogenically transformed cells. Proc Natl Acad Sci U S A 92(5): 1381-1385. 
Kolligs, F. T., G. Bommer, et al. (2002). Wnt/beta-catenin/tcf signaling: a critical pathway in 
gastrointestinal tumorigenesis. Digestion 66(3): 131-144. 
Kreizenbeck, G. M., A. J. Berger, et al. (2008). Prognostic significance of cadherin-based 
adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers 
Prev 17(4): 949-958. 
Labrecque, L., C. Nyalendo, et al. (2004). Src-mediated tyrosine phosphorylation of caveolin-
1 induces its association with membrane type 1 matrix metalloproteinase. J Biol 
Chem 279(50): 52132-52140. 
Larue, L. and V. Delmas (2006). The WNT/Beta-catenin pathway in melanoma. Front Biosci 
11: 733-742. 
Larue, L., F. Luciani, et al. (2009). Bypassing melanocyte senescence by beta-catenin: a novel 
way to promote melanoma. Pathol Biol (Paris) 57(7-8): 543-547. 
Lavie, Y., G. Fiucci, et al. (1998). Up-regulation of caveolae and caveolar constituents in 
multidrug-resistant cancer cells. J Biol Chem 273(49): 32380-32383. 
www.intechopen.com
 Advances in Malignant Melanoma – Clinical and Research Perspectives 210 
Lavie, Y. and M. Liscovitch (2000). Changes in lipid and protein constituents of rafts and 
caveolae in multidrug resistant cancer cells and their functional consequences. 
Glycoconj J 17(3 -4): 253-259. 
Lee, H., D. Volonte, et al. (2000). Constitutive and growth factor-regulated phosphorylation 
of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-
1/Grb7 signaling cassette. Mol Endocrinol 14(11): 1750-1775. 
Lee, S. W., C. L. Reimer, et al. (1998). Tumor cell growth inhibition by caveolin re-expression 
in human breast cancer cells. Oncogene 16(11): 1391-1397. 
Levy, C., M. Khaled, et al. (2006). MITF: master regulator of melanocyte development and 
melanoma oncogene. Trends Mol Med 12(9): 406-414. 
Li, F., G. Ambrosini, et al. (1998). Control of apoptosis and mitotic spindle checkpoint by 
survivin. Nature 396(6711): 580-584. 
Li, L., C. Ren, et al. (2009). Caveolin-1 promotes autoregulatory, Akt-mediated induction of 
cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 7(11): 
1781-1791. 
Li, L., G. Yang, et al. (2001). Caveolin-1 mediates testosterone-stimulated survival/clonal 
growth and promotes metastatic activities in prostate cancer cells. Cancer Res 
61(11): 4386-4392. 
Li, S., R. Seitz, et al. (1996). Phosphorylation of caveolin by src tyrosine kinases. The alpha-
isoform of caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem 
271(7): 3863-3868. 
Logan, C. Y. and R. Nusse (2004). The Wnt signaling pathway in development and disease. 
Annu Rev Cell Dev Biol 20: 781-810. 
Logozzi, M., A. De Milito, et al. (2009). High levels of exosomes expressing CD63 and 
caveolin-1 in plasma of melanoma patients. PLoS One 4(4): e5219. 
Lucero, O. M., D. W. Dawson, et al. A re-evaluation of the oncogenic nature of Wnt/beta-
catenin signaling in melanoma and other cancers. Curr Oncol Rep 12(5): 314-318. 
Llorente, A., M. C. de Marco, et al. (2004). Caveolin-1 and MAL are located on prostasomes 
secreted by the prostate cancer PC-3 cell line. J Cell Sci 117(Pt 22): 5343-5351. 
Ma, L., J. Young, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin 
and cancer metastasis. Nat Cell Biol 12(3): 247-256. 
Maelandsmo, G. M., R. Holm, et al. (2003). Reduced beta-catenin expression in the 
cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin 
Cancer Res 9(9): 3383-3388. 
Margineanu, E., C. E. Cotrutz, et al. (2008). Correlation between E-cadherin abnormal 
expressions in different types of cancer and the process of metastasis. Rev Med Chir 
Soc Med Nat Iasi 112(2): 432-436. 
Mastick, C. C., M. J. Brady, et al. (1995). Insulin stimulates the tyrosine phosphorylation of 
caveolin. J Cell Biol 129(6): 1523-1531. 
Mastick, C. C. and A. R. Saltiel (1997). Insulin-stimulated tyrosine phosphorylation of 
caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. J Biol 
Chem 272(33): 20706-20714. 
McDonald, S. L. and A. Silver (2009). The opposing roles of Wnt-5a in cancer. Br J Cancer 
101(2): 209-214. 
www.intechopen.com
 Caveolin-1 in Melanoma Progression 211 
Nakashima, H., K. Hamamura, et al. (2007). Overexpression of caveolin-1 in a human 
melanoma cell line results in dispersion of ganglioside GD3 from lipid rafts and 
alteration of leading edges, leading to attenuation of malignant properties. Cancer 
Sci 98(4): 512-520. 
Nathke, I. S. (2004). The adenomatous polyposis coli protein: the Achilles heel of the gut 
epithelium. Annu Rev Cell Dev Biol 20: 337-366. 
Nicolson, G. L., K. W. Brunson, et al. (1978). Specificity of arrest, survival, and growth of 
selected metastatic variant cell lines. Cancer Res 38(11 Pt 2): 4105-4111. 
O'Connell, M. P. and A. T. Weeraratna (2009). Hear the Wnt Ror: how melanoma cells adjust 
to changes in Wnt. Pigment Cell Melanoma Res 22(6): 724-739. 
Okamoto, T., A. Schlegel, et al. (1998). Caveolins, a family of scaffolding proteins for 
organizing preassembled signaling complexes at the plasma membrane. J Biol Chem 
273(10): 5419-5422. 
Orlichenko, L., B. Huang, et al. (2006). Epithelial growth factor-induced phosphorylation of 
caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells. J Biol 
Chem 281(8): 4570-4579. 
Parat, M. O., B. Anand-Apte, et al. (2003). Differential caveolin-1 polarization in 
endothelial cells during migration in two and three dimensions. Mol Biol Cell 
14(8): 3156-3168. 
Park, D. S., A. W. Cohen, et al. (2003). Caveolin-1 null (-/-) mice show dramatic reductions 
in life span. Biochemistry 42(51): 15124-15131. 
Pecina-Slaus, N., M. Zigmund, et al. (2007). E-cadherin and beta-catenin expression patterns 
in malignant melanoma assessed by image analysis. J Cutan Pathol 34(3): 239-246. 
Polakis, P. (2000). Wnt signaling and cancer. Genes Dev 14(15): 1837-1851. 
Ponder, B. A. (2001). Cancer genetics. Nature 411(6835): 336-341. 
Quest, A. F., J. L. Gutierrez-Pajares, et al. (2008). Caveolin-1: an ambiguous partner in cell 
signalling and cancer. J Cell Mol Med 12(4): 1130-1150. 
Quest, A. F., L. Leyton, et al. (2004). Caveolins, caveolae, and lipid rafts in cellular transport, 
signaling, and disease. Biochem Cell Biol 82(1): 129-144. 
Racine, C., M. Belanger, et al. (1999). Reduction of caveolin 1 gene expression in lung 
carcinoma cell lines. Biochem Biophys Res Commun 255(3): 580-586. 
Razani, B., J. A. Engelman, et al. (2001). Caveolin-1 null mice are viable but show evidence of 
hyperproliferative and vascular abnormalities. J Biol Chem 276(41): 38121-38138. 
Razani, B., A. Schlegel, et al. (2000). Caveolin proteins in signaling, oncogenic 
transformation and muscular dystrophy. J Cell Sci 113 ( Pt 12): 2103-2109. 
Razani, B., S. E. Woodman, et al. (2002). Caveolae: from cell biology to animal physiology. 
Pharmacol Rev 54(3): 431-467. 
Reed, J. C. (2001). The Survivin saga goes in vivo. J Clin Invest 108(7): 965-969. 
Rimm, D. L., K. Caca, et al. (1999). Frequent nuclear/cytoplasmic localization of beta-catenin 
without exon 3 mutations in malignant melanoma. Am J Pathol 154(2): 325-329. 
Rodriguez, D. A., J. C. Tapia, et al. (2009). Caveolin-1-mediated suppression of 
cyclooxygenase-2 via a beta-catenin-Tcf/Lef-dependent transcriptional mechanism 
reduced prostaglandin E2 production and survivin expression. Mol Biol Cell 20(8): 
2297-2310. 
www.intechopen.com
 Advances in Malignant Melanoma – Clinical and Research Perspectives 212 
Sanguinetti, A. R. and C. C. Mastick (2003). c-Abl is required for oxidative stress-induced 
phosphorylation of caveolin-1 on tyrosine 14. Cell Signal 15(3): 289-298. 
Santilman, V., J. Baran, et al. (2007). Caveolin-1 polarization in transmigrating endothelial 
cells requires binding to intermediate filaments. Angiogenesis 10(4): 297-305. 
Savage, K., M. B. Lambros, et al. (2007). Caveolin 1 is overexpressed and amplified in a 
subset of basal-like and metaplastic breast carcinomas: a morphologic, 
ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin 
Cancer Res 13(1): 90-101. 
Scherer, P. E., Z. Tang, et al. (1995). Caveolin isoforms differ in their N-terminal protein 
sequence and subcellular distribution. Identification and epitope mapping of an 
isoform-specific monoclonal antibody probe. J Biol Chem 270(27): 16395-16401. 
Schmalhofer, O., S. Brabletz, et al. (2009). E-cadherin, beta-catenin, and ZEB1 in malignant 
progression of cancer. Cancer Metastasis Rev 28(1-2): 151-166. 
Shtutman, M., J. Zhurinsky, et al. (1999). The cyclin D1 gene is a target of the beta-
catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 96(10): 5522-5527. 
Sloan, E. K., D. R. Ciocca, et al. (2009). Stromal cell expression of caveolin-1 predicts outcome 
in breast cancer. Am J Pathol 174(6): 2035-2043. 
Straume, O. and L. A. Akslen (1997). Alterations and prognostic significance of p16 and p53 
protein expression in subgroups of cutaneous melanoma. Int J Cancer 74(5): 535-
539. 
Sun, X. H., D. C. Flynn, et al. (2007). Identification of a novel domain at the N terminus of 
caveolin-1 that controls rear polarization of the protein and caveolae formation. J 
Biol Chem 282(10): 7232-7241. 
Sun, X. H., Z. Y. Liu, et al. (2009). A conserved sequence in caveolin-1 is both necessary and 
sufficient for caveolin polarity and cell directional migration. FEBS Lett 583(22): 
3681-3689. 
Tahir, S. A., S. Park, et al. (2009). Caveolin-1 regulates VEGF-stimulated angiogenic activities 
in prostate cancer and endothelial cells. Cancer Biol Ther 8(23): 2286-2296 
Tahir, S. A., G. Yang, et al. (2001). Secreted caveolin-1 stimulates cell survival/clonal growth 
and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 
61(10): 3882-3885. 
Torres, V. A., J. C. Tapia, et al. (2007). E-cadherin is required for caveolin-1-mediated down-
regulation of the inhibitor of apoptosis protein survivin via reduced beta-catenin-
Tcf/Lef-dependent transcription. Mol Cell Biol 27(21): 7703-7717. 
Torres, V. A., J. C. Tapia, et al. (2006). Caveolin-1 controls cell proliferation and cell death by 
suppressing expression of the inhibitor of apoptosis protein survivin. J Cell Sci 
119(Pt 9): 1812-1823. 
Trimmer, C., D. Whitaker-Menezes, et al. (2010). CAV1 inhibits metastatic potential in 
melanomas through suppression of the integrin/Src/FAK signaling pathway. 
Cancer Res 70(19): 7489-7499. 
Tucci, M. G., G. Lucarini, et al. (2007). Involvement of E-cadherin, beta-catenin, Cdc42 and 
CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 
157(6): 1212-1216. 
www.intechopen.com
 Caveolin-1 in Melanoma Progression 213 
van Deurs, B., K. Roepstorff, et al. (2003). Caveolae: anchored, multifunctional platforms in 
the lipid ocean. Trends Cell Biol 13(2): 92-100. 
Volonte, D., F. Galbiati, et al. (2001). Cellular stress induces the tyrosine phosphorylation of 
caveolin-1 (Tyr(14)) via activation of p38 mitogen-activated protein kinase and c-
Src kinase. Evidence for caveolae, the actin cytoskeleton, and focal adhesions as 
mechanical sensors of osmotic stress. J Biol Chem 276(11): 8094-8103. 
Watanabe, M., G. Yang, et al. (2009). Functional analysis of secreted caveolin-1 in mouse 
models of prostate cancer progression. Mol Cancer Res 7(9): 1446-1455. 
Weinberg, R. A. (1989). Oncogenes, antioncogenes, and the molecular bases of multistep 
carcinogenesis. Cancer Res 49(14): 3713-3721. 
Widelitz, R. (2005). Wnt signaling through canonical and non-canonical pathways: recent 
progress. Growth Factors 23(2): 111-116. 
Widlund, H. R., M. A. Horstmann, et al. (2002). Beta-catenin-induced melanoma growth 
requires the downstream target Microphthalmia-associated transcription factor. J 
Cell Biol 158(6): 1079-1087. 
Wiechen, K., L. Diatchenko, et al. (2001). Caveolin-1 is down-regulated in human ovarian 
carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159(5): 1635-
1643. 
Wiechen, K., C. Sers, et al. (2001). Down-regulation of caveolin-1, a candidate tumor 
suppressor gene, in sarcomas. Am J Pathol 158(3): 833-839. 
Williams, T. M., M. W. Cheung, et al. (2003). Loss of caveolin-1 gene expression accelerates 
the development of dysplastic mammary lesions in tumor-prone transgenic mice. 
Mol Biol Cell 14(3): 1027-1042. 
Williams, T. M. and M. P. Lisanti (2004). The caveolin proteins. Genome Biol 5(3): 214. 
Williams, T. M. and M. P. Lisanti (2005). Caveolin-1 in oncogenic transformation, cancer, 
and metastasis. Am J Physiol Cell Physiol 288(3): C494-506. 
Witkiewicz, A. K., A. Dasgupta, et al. (2009). An absence of stromal caveolin-1 expression 
predicts early tumor recurrence and poor clinical outcome in human breast cancers. 
Am J Pathol 174(6): 2023-2034. 
Wu, Y., Y. Lin, et al. (2008). Inhibition of invasion and up-regulation of E-cadherin 
expression in human malignant melanoma cell line A375 by (-)-epigallocatechin-3-
gallate. J Huazhong Univ Sci Technolog Med Sci 28(3): 356-359. 
Yamaguchi, H., Y. Takeo, et al. (2009). Lipid rafts and caveolin-1 are required for 
invadopodia formation and extracellular matrix degradation by human breast 
cancer cells. Cancer Res 69(22): 8594-8602. 
Yang, G., J. Addai, et al. (2007). Correlative evidence that prostate cancer cell-derived 
caveolin-1 mediates angiogenesis. Hum Pathol 38(11): 1688-1695. 
Yang, G., L. D. Truong, et al. (1998). Elevated expression of caveolin is associated with 
prostate and breast cancer. Clin Cancer Res 4(8): 1873-1880. 
Zhang, H., L. Su, et al. (2008). Restoration of caveolin-1 expression suppresses growth 
and metastasis of head and neck squamous cell carcinoma. Br J Cancer 99(10): 
1684-1694. 
www.intechopen.com
 Advances in Malignant Melanoma – Clinical and Research Perspectives 214 
Zhu, D. Z., C. F. Cheng, et al. (1991). Mediation of lung metastasis of murine melanomas by 
a lung-specific endothelial cell adhesion molecule. Proc Natl Acad Sci U S A 88(21): 
9568-9572. 
www.intechopen.com
Advances in Malignant Melanoma - Clinical and Research
Perspectives
Edited by Dr. April Armstrong
ISBN 978-953-307-575-4
Hard cover, 252 pages
Publisher InTech
Published online 22, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book titled Advances in Malignant Melanoma - Clinical and Research Perspectives represents an
international effort to highlight advances in our understanding of malignant melanoma from both clinical and
research perspectives. The authors for this book consist of an international group of recognized leaders in
melanoma research and patient care, and they share their unique perspectives regarding melanoma
epidemiology, risk factors, diagnostic and prognostic tools, phenotypes, treatment, and future research
directions. The book is divide into four sections: (1) Epidemiology and Risk Factors of Melanoma, (2) Clinical
Phenotypes of Melanoma, (3) Investigational Treatments for Melanoma and Pigmentary Disorders, and (4)
Advances in Melanoma Translational Research. This book does not attempt to exhaustively cover all aspects
of the aforementioned topics. Rather, it is a compilation of our authorsâ€™ pearls and unique perspectives on
the relevant advances in melanoma during the recent years.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Lorena Lobos-Gonza ́lez, Lorena Aguilar, Gonzalo Ferna ́ndez, Carlos Sanhueza and Andrew F.G Quest
(2011). Caveolin-1 in Melanoma Progression, Advances in Malignant Melanoma - Clinical and Research
Perspectives, Dr. April Armstrong (Ed.), ISBN: 978-953-307-575-4, InTech, Available from:
http://www.intechopen.com/books/advances-in-malignant-melanoma-clinical-and-research-
perspectives/caveolin-1-in-melanoma-progression
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
